Patients With Typical Symptoms of GERD (GERD Q >= 8)
Conditions
Keywords
Proton Pump Inhibitor, GERD, GERD Q
Brief summary
China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients with Gastroesophageal Reflux Disease
Detailed description
To estimate the overall responder rate after 4 weeks of Proton Pump Inhibitor empirical treatment This will be a multicenter prospective observational study carried out in China. Investigator will collect data in a pre-specified Case Report Form from the outpatient. Informed consents will be needed. Investigator will provide patient diary card to each patient for them to note down the symptom frequency every day. Main data from each outpatient will include demographics, Gerd Q, symptom frequency and Proton Pump Inhibitor empirical treatment. Data from each outpatient will be collected on the screening day, 2 weeks and 4 weeks.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female or male, and any race, Age ≥ 18 years and≤ 65 outpatients. * Gastroenterologists already prescribe PPI standard dose bid as empirical treatment. * GerdQ≥8 * The subject will not have endoscopy within 4 weeks after enrolment. * Ability to provide informed consent, adhere to the study visit schedule, and complete all study assessments and complete the patient diary by his/herself.
Exclusion criteria
* If participating in any interventional clinical trial. * Patient with alarm symptom of oncology(weight loss, recurrent dysphagia, anemia, hematemesis, melena). * Continuous application of nonsteroidal anti-inflammation drugs or acid suppressive drug within 2 weeks before screening. * The need for H2-receptor antagonists (H2RA) including cimetidine, ranitidine and famotidine or sucralfate, antacids, traditional Chinese medicine and prokinetics during the upcoming 4 weeks (study duration). * Previous gastroesophageal surgery. * Upper gastrointestinal malignancy, achalasia, and esophageal spasm or stricture. * Peptic ulcer * Diabetes * Cerebral vascular disease * Zollinger-Ellison syndrome * Scleroderma * Hiatus hernia women * Pregnant or lactating women * Any other subjects were not suitable to this study in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The overall responder rate | After 4 weeks of Proton Pump Inhibitor empirical treatment | The overall responder rate after 4 weeks of Proton Pump Inhibitor empirical treatment. Responder is defined as heartburn/regurgitation frequency ≤1 days during 7 days before evaluation visit, assessed using Gerd Q questionnaire at each post-baseline visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The overall responder rate | After 2 weeks of Proton Pump Inhibitor empirical treatment | The overall responder rate after 2 weeks of Proton Pump Inhibitor empirical treatment |
| The proportion of patients in each Gerd Q cut-off range at each visit | At each visit (baseline, 2 weeks and 4 weeks) | The proportion of patients in each Gerd Q cut-off range at each visit (Gerd Q range: ≤2; 3-7; 8-10; 11-18) |
| The responder rate of different Proton Pump Inhibitor empirical treatment | After 2 and 4 weeks of different PPIs empirical treatment | The responder rate respectively after 2 and 4 weeks of different Proton Pump Inhibitor empirical treatment |
| The median time to response overall and for different Proton Pump Inhibitor, respectively | During 4 weeks of whole study | The median time to response (heartburn/regurgitation frequency ≤1 days during last 7 days assessed using patient's diary card) overall and for different Proton Pump Inhibitor, respectively |
Countries
China
Outcome results
None listed